Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment
NCT06948149, Not applicable, Recruiting, Western University, Canada
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT06948149 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 140 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Western University, Canada | ClinicalTrials.gov |
| Conditions | Creatine, Exercise, Mild Cognitive Impairment (MCI) | ClinicalTrials.gov |
| Interventions | Creatine monohydrate, Resistance training | ClinicalTrials.gov |
| First posted | 2025-04-29 | ClinicalTrials.gov |
| Last updated | 2026-08-20 | ClinicalTrials.gov |
Registered outcomes 26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Corsi Span - Corsi Block Tapping Task | Baseline and 26 weeks | Visuospatial working memory will be assessed using the forward and reverse Corsi block-tapping task. Participants will be given an iPad to complete the task. In this task, participants will see nine BLUE blocks on the screen. For each trial, a sequence of blocks will turn RED one by one. Their task is to remember the order in which the blocks light up and then repeat the sequence in the same order (forward Corsi) or backwards (reverse Corsi) by tapping on the blocks. Participants will first complete two practice trials before the true trials to ensure that the instructions are understood. Sequences will become increasingly more difficult with a maximum sequence of nine and a minimum of two. The maximum sequence number that each participant correctly reproduces (Corsi span) will be measured, where higher scores indicate better visuospatial working memory. | ClinicalTrials.gov |
| Primary | Reaction Time - Corsi Block Tapping Task | Baseline and 26 weeks | Visuospatial working memory will be assessed using the forward and reverse Corsi block-tapping task. Participants will be given an iPad to complete the task. In this task, participants will see nine BLUE blocks on the screen. For each trial, a sequence of blocks will turn RED one by one. Their task is to remember the order in which the blocks light up and then repeat the sequence in the same order (forward Corsi) or backwards (reverse Corsi) by tapping on the blocks. Participants will first complete two practice trials before the true trials to ensure that the instructions are understood. Sequences will become increasingly more difficult with a maximum sequence of nine and a minimum of two. Reaction time, or how fast the participant can reproduce each sequence, will be measured. | ClinicalTrials.gov |
| Secondary | Interference Score - Stroop Task | Baseline and 26 weeks | Investigators will examine the interference score for each participant using the Stroop task. Participants are required to read the colour of the ink that each word is printed in and inhibit what the word actually says. The time to complete this test is recorded in seconds. Higher scores reflect better performance and less interference. | ClinicalTrials.gov |
| Secondary | Span Capacity - Digits Forward and Backward Subtests | Baseline and 26 weeks | Working memory using the Digits Forward and Backward subtests. Participants are required to memorize and recall a series of number lists both forward and backward. Span capacity (the largest sequence to be recalled) will be measured. The minimum sequence for the forward test is three and the maximum is nine. The minimum sequence for the backward test is two and the maximum is eight. Higher sequences reproduced indicate better working memory. | ClinicalTrials.gov |
| Secondary | Time - Trail Making Test (Part B) | Baseline and 26 weeks | Mental flexibility using the Trail Making Test (Part B). Participants will have to alternate between numbers and letters without removing the pen from the page. The time to complete this test is recorded in seconds. | ClinicalTrials.gov |
| Secondary | Memory Score - Rey Auditory Verbal Learning Test | Baseline and 26 weeks | Participants are read a list of 15 words five times and asked to recall verbally as many as possible. They are then given a separate (interference) list of words and then need to recall the original list immediately after (immediate recall 0 and again after a 20-minute delay (delayed recall). | ClinicalTrials.gov |
| Secondary | Time - Timed Up & Go (TUG) Test | Baseline and 26 weeks | A test of functional mobility. Participants are seated in a chair and must stand up, walk three meters at their usual pace, turn around, return to their chair, and sit back down. The time to complete each of two separate trials is recorded in seconds. Time will be averaged between the two trials. | ClinicalTrials.gov |
| Secondary | Short Physical Performance Battery (SPPB) Score | Baseline and 26 weeks | Used to assess gait speed, balance, and lower extremity physical function using tasks that mimic daily activities; includes three tasks: 1. Standing Balance Task: participants stand unassisted (side-by-side standing, semi-tandem standing, and tandem standing) for a period of 10 seconds each; 2. Walking Speed Task: participants walk 4 metres at their usual pace; and 3. Chair Stand Test: participants stand up from a chair 5 times consecutively (without the use of their arms if possible). For task 1, participants receive the point(s) if they can hold the balance task for at least 10 seconds. Time to complete tasks 2 and 3 is recorded in seconds. The task is scored out of 12, with higher scores indicating better physical performance. | ClinicalTrials.gov |
| Secondary | Number of Falls - Falls History and Prospective Reporting | Baseline, 26 weeks, and when they occur | We will record the number of falls participants have experienced and details about how each fall occurred. The questionnaire asks the participant if they have fallen in the past six months. If no, the questionnaire is complete. If yes, participants continue to answer questions about the fall(s) (e.g., number of falls, any injuries, who witnessed the fall). Additionally, because declines in mobility are known to co-occur with declines in cognition, we will also monitor falls throughout the study duration to further characterize our sample and reduce recall bias. Participants will be asked to note falls in their calendar if they occur, which will be returned to the lab monthly for review by exercise personnel. | ClinicalTrials.gov |
| Secondary | Estimated One Repetition Maximum (E1RM) - Muscle Strength | Baseline, midpoint, and 26 weeks | One-repetition maximum is a physical measure of an individual's maximum muscle strength. We will calculate E1RM by having participants complete \> 8 of each exercise to failure, and we will derive an E1RM based on the weight and number of repetitions completed by using the Brzycki Formula. Exercises includes leg press, latissimus pulldown, leg curl, chest press, bicep curls, tricep extensions, and pulley rows. | ClinicalTrials.gov |
| Secondary | Grip Strength | Baseline and 26 weeks | Measured using a calibrated hand dynamometer. Participants will be instructed to sit with their elbow at 90 degrees, wrist in a neutral position, and squeeze the dynamometer with maximal effort for 3-5 seconds. Three trials will be performed and recorded per hand, with 30 seconds of rest between attempts. | ClinicalTrials.gov |
| Secondary | Bone Density | Baseline and 26 weeks | Observed via dual-energy x-ray absorptiometry (DEXA or DXA). This is a common, non-invasive method often used to identify osteoporosis and fracture risk in older adults. Participants lay still on a padded table and an x-ray is taken of their entire body. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Phosphorylated Tau 217 (p tau 217) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. Higher levels of p tau 217 biomarker in blood plasma may suggest cognitive decline and progression to Alzheimer's disease. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Neurofilament Light Chain (NfL) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. Higher plasma NfL levels are associated with cognitive decline. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Glial Fibrillary Acidic Protein (GFAP) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. Elevated GFAP plasma levels have been shown to be elevated in those with cognitive decline. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Amyloid Beta 42 (Aβ42) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. Low levels of Aβ42 in plasma have been linked to cognitive decline. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Creatinine | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. Creatinine is a waste product formed from creatine breakdown. Creatinine levels in blood plasma should be elevated with creatine supplementation. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Brain-Derived Neurotrophic Factor (BDNF) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. BDNF is important for neuronal growth and plasticity. Some studies suggest that BDNF plasma levels may be lower in individuals with cognitive decline. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Insulin-like Growth Factor 1 (IGF-1) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. IGF-1 promotes neuronal growth and better cognitive function. Lower IGF-1 plasma levels are associated with cognitive decline. | ClinicalTrials.gov |
| Secondary | Biomarker Concentration - Interleukin 6 (IL-6) | Baseline and 26 weeks | Measured from blood samples and examined using a blood assay kit. Elevated IL-6 levels in blood plasma are associated with poorer cognitive performance and an increased risk of cognitive decline. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 14
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 15005868 | BACKGROUND | PubMed |
| 17828627 | BACKGROUND | PubMed |
| 21394604 | BACKGROUND | PubMed |
| 22529236 | BACKGROUND | PubMed |
| 23554283 | BACKGROUND | PubMed |
| 28459277 | BACKGROUND | PubMed |
| 30762623 | BACKGROUND | PubMed |
| 30978926 | BACKGROUND | PubMed |
| 31333805 | BACKGROUND | PubMed |
| 33502271 | BACKGROUND | PubMed |
| 33578876 | BACKGROUND | PubMed |
| 36673844 | BACKGROUND | PubMed |
| 40971619 | BACKGROUND | PubMed |
| 40977987 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Corsi Block-Tapping Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)